Literature DB >> 21718664

Targeting STAT3 in hepatocellular carcinoma: sorafenib again….

Olivier Rosmorduc, Christèle Desbois-Mouthon.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21718664     DOI： 10.1016/j.jhep.2011.06.005

Source DB:  PubMed          Journal:  J Hepatol        ISSN： 0168-8278            Impact factor:   25.083


× No keyword cloud information.
  12 in total

Review 1.  STAT proteins - key regulators of anti-viral responses, inflammation, and tumorigenesis in the liver.

Authors:  Bin Gao; Hua Wang; Fouad Lafdil; Dechun Feng
Journal:  J Hepatol       Date:  2012-04-12       Impact factor: 25.083

2.  Development of a novel azaspirane that targets the Janus kinase-signal transducer and activator of transcription (STAT) pathway in hepatocellular carcinoma in vitro and in vivo.

Authors:  Chakrabhavi Dhananjaya Mohan; Hanumantharayappa Bharathkumar; Krishna C Bulusu; Vijay Pandey; Shobith Rangappa; Julian E Fuchs; Muthu K Shanmugam; Xiaoyun Dai; Feng Li; Amudha Deivasigamani; Kam M Hui; Alan Prem Kumar; Peter E Lobie; Andreas Bender; Gautam Sethi; Kanchugarakoppal S Rangappa
Journal:  J Biol Chem       Date:  2014-10-15       Impact factor: 5.157

3.  Receptor interacting protein 1 knockdown induces cell death in liver cancer by suppressing STAT3/ATR activation in a p53-dependent manner.

Authors:  Seung-Youn Jung; Jeong-In Park; Jae-Hoon Jeong; Kyung-Hee Song; Jiyeon Ahn; Sang-Gu Hwang; Jaesung Kim; Jong-Kuk Park; Dae-Seog Lim; Jie-Young Song
Journal:  Am J Cancer Res       Date:  2022-06-15       Impact factor: 5.942

4.  Synergistic interaction between the HDAC inhibitor, MPT0E028, and sorafenib in liver cancer cells in vitro and in vivo.

Authors:  Jing-Ping Liou; Shiow-Lin Pan; Che-Ming Teng; Chun-Han Chen; Mei-Chuan Chen; Jing-Chi Wang; An-Chi Tsai; Ching-Shih Chen
Journal:  Clin Cancer Res       Date:  2014-02-11       Impact factor: 12.531

Review 5.  Current systemic treatment of hepatocellular carcinoma: A review of the literature.

Authors:  Kai-Wen Chen; Tzu-Ming Ou; Chin-Wen Hsu; Chi-Ting Horng; Ching-Chang Lee; Yuh-Yuan Tsai; Chi-Chang Tsai; Yi-Sheng Liou; Chen-Chieh Yang; Chao-Wen Hsueh; Wu-Hsien Kuo
Journal:  World J Hepatol       Date:  2015-06-08

6.  Effects of Sorafenib Dose on Acquired Reversible Resistance and Toxicity in Hepatocellular Carcinoma.

Authors:  Elizabeth A Kuczynski; Christina R Lee; Shan Man; Eric Chen; Robert S Kerbel
Journal:  Cancer Res       Date:  2015-04-23       Impact factor: 12.701

7.  Sorafenib and DE605, a novel c-Met inhibitor, synergistically suppress hepatocellular carcinoma.

Authors:  Xiufeng Jiang; Kang Feng; Ye Zhang; Zengyao Li; Fan Zhou; Huiqiang Dou; Tong Wang
Journal:  Oncotarget       Date:  2015-05-20

8.  Synergistic Activity of N-hydroxy-7-(2-naphthylthio) Heptanomide and Sorafenib Against Cancer Stem Cells, Anaplastic Thyroid Cancer.

Authors:  Ki Cheong Park; Seok-Mo Kim; Jeong Yong Jeon; Bup-Woo Kim; Hyeung Kyoo Kim; Ho Jin Chang; Yong Sang Lee; Soo Young Kim; Seung Hoon Choi; Cheong Soo Park; Hang-Seok Chang
Journal:  Neoplasia       Date:  2017-01-28       Impact factor: 5.715

9.  Mcl-1-dependent activation of Beclin 1 mediates autophagic cell death induced by sorafenib and SC-59 in hepatocellular carcinoma cells.

Authors:  W-T Tai; C-W Shiau; H-L Chen; C-Y Liu; C-S Lin; A-L Cheng; P-J Chen; K-F Chen
Journal:  Cell Death Dis       Date:  2013-02-07       Impact factor: 8.469

10.  Personalized identification of tumor-associated immunogenic neoepitopes in hepatocellular carcinoma in complete remission after sorafenib treatment.

Authors:  Sindy Vrecko; David Guenat; Patricia Mercier-Letondal; Hugues Faucheu; Magalie Dosset; Bernard Royer; Jeanne Galaine; Romain Boidot; Stefano Kim; Marine Jary; Olivier Adotévi; Christophe Borg; Yann Godet
Journal:  Oncotarget       Date:  2018-10-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.